arrow
N

Nicoletta Bivi

us food & drug administration (fda)
H指数:21
被引数:2,405

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A-Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B-Regulatory Agencies' Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))

2025年生物分析近期问题白皮书:生物标志物校准与稳定性;NULISA评估;神经丝蛋白与自身抗体生物标志物检测;去除IgM干扰;ELISpot与FluoroSpot最佳实践;模块化高维度细胞计数;单细胞分析成像细胞计数(第二部分A-关于生物标志物发现、开发、验证与监管批准、配体结合检测(LBA)和细胞基础检测(CBA)的建议;第二部分B-监管机构对生物标志物、体外诊断(IVD)/伴随诊断(CDx)和生物标志物检测验证(BAV)的反馈)

2026-01-011
PRE
Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules

亲和捕获-洗脱结合细胞基环腺苷酸测定法,作为一种检测抑制素分子中和抗体的平台方法

2025-10-130
PRE
Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure
2023-03-0814
OA